1. Dose–Response Evaluation of Scopoletin, a Phytochemical, in a High-Fructose High-Fat Diet-Induced Dyslipidemia Model in Wistar Rats.
- Author
-
Batra, Gurpreet Kaur, Mothsara, Chakrant, Sharma, Swati, Anand, Aishwarya, Bhatia, Alka, Bhansali, Shobhit, Ram, Sant, Pal, Arnab, and Patil, Amol N.
- Subjects
- *
DRUG therapy for hyperlipidemia , *BIOLOGICAL models , *TRIGLYCERIDES , *DRUG efficacy , *ANTILIPEMIC agents , *AYURVEDIC medicine , *ANIMAL experimentation , *ORAL drug administration , *INTRAPERITONEAL injections , *LOW density lipoproteins , *PHYTOCHEMICALS , *RATS , *COMPARATIVE studies , *BENZOPYRANS , *DOSE-effect relationship in pharmacology , *DESCRIPTIVE statistics , *CHOLESTEROL , *PHARMACODYNAMICS - Abstract
The putative hypolipidemic properties of scopoletin have not been fully confirmed due to a lack of validation in an irreversible chronic hyperlipidemia animal model. The druggability also needs to be studied in terms of bioavailability in the vascular compartment. Accordingly, we conducted a study to assess the hypolipidemic and pharmacokinetic behavior of scopoletin in the high-fructose high-fat diet (HFHFD)-induced dyslipidemia model in Wistar rats. A total of 42 rats were studied, with 6 in each of the 7 groups. A 60-day HFHFD opted for induction of dyslipidemia. Group I and groups II–VII received normal rat chow diet and HFHFD, respectively. Oral scopoletin (1, 5, 10 mg/kg) and atorvastatin 5 mg/kg were administered in groups III–VI, respectively, once daily for the next 15 days. A separate group, group VII, was used for the pharmacokinetic assessment comparing the scopoletin 10 mg/kg intraperitoneally (IP) in group VII versus the oral (group V). Pharmacokinetic blood sampling was performed on the 10th day of continuous once-daily therapy. Rats were sacrificed for the histological examination. All three scopoletin dosages significantly decreased the total cholesterol, low-density lipoproteins, and triglycerides (P < .05 for all), but not in a dose-dependent manner. Atherogenic Index of plasma, Castelli's risk indices, and histopathological findings confirmed the protective effect of scopoletin. The IP administration showed a 23.18% higher exposure than the oral route (P < .001 for area under the curve and P < .05 for concentration-maximum). This study confirms the hypolipidemic efficacy of scopoletin in a more robust irreversible model of dyslipidemia. Scopoletin's gut absorption in the disease state may also boost the initial phase exploratory clinical trial. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF